Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J

CONCLUSIONS: HP was active in a selection of HER2-amplified tumors (non-breast/gastroesophageal) but did not meet the predefined efficacy benchmark. Additional strategies targeting HER2 and potential resistance pathways are warranted, especially in rare tumors.PMID:38433347 | DOI:10.1158/1078-0432.CCR-23-0633

Source: Clinical Colorectal Cancer - March 4, 2024 Category: Cancer & Oncology Authors: Roisin M Connolly Victoria Wang David M Hyman Petros Grivas Edith P Mitchell John J Wright Elad Sharon Robert J Gray Lisa M McShane Larry V Rubinstein David R Patton P Mickey Williams Stanley R Hamilton Jue Wang Kari B Wisinski James V Tricoli Barbara A C Source Type: research